AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05424159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Description: Patients with locally advanced unresectable pancreatic cancer without invasion of gastrointestinal tract will received ablative carbon ion radiotherapy. The prescription dose for primary pancreatic lesion, positive lymph node, and retroperitoneal high-risk recurrence area is 67.5 Gy (RBE weighted dose) in 15 fractions for 3 weeks; Pancreatic primary lesion and positive lymph node SIB to 75 Gy (RBE weighted dose) in 15 fractions for 3 weeks.
Study NCT05100329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome injection
Description: 20 mg/m\^2, IV, on day 1 of every 3 weeks (q3w, a cycle)
Study NCT04940676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huzhangxiefei Decoction
Description: Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Study NCT04940676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 10% Huzhangxiefei Decoction
Description: 10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Study NCT05043818 — intervention group
Intervention type: OTHER
Description: This study is an observational study and does not involve intervention.When the patient comes to the hospital or on the first to the second day of admission, the subject will be given a full scale check once（Screening related scales for anxiety and depression symptoms (PHQ9, SDS, HADS, HAMA, HAMD), inflammatory bowel disease quality of life scale (IBDQ), modified Mayo score for patients with ulcerative colitis/ simplified CDAI score for patients with Crohn's disease , Stool characteristics, degree of abdominal pain, gastrointestinal symptom scale (GSRS), etc.）. The stool sample will be collected once and 16S rRNA sequencing.
Study NCT04586712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active CBD
Description: Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
Study NCT04586712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control (Placebo)
Description: Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
Study NCT06317688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra-Virgin Coconut Oil
Description: Active ingredients act as a destructor of bacteria, viruses and fungus
Study NCT06453460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
Study NCT06453460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMV T Cell Immunity Panel (CMV-TCIP)
Description: Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
Study NCT06453460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMV DNA PCR
Description: Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
Study NCT06516913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe Pump
Description: Used to administer buffer solution with hyaluronic acid SC
Study NCT05468372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 600 mg followed by posaconazole 300 mg once daily
Description: Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
Study NCT05468372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment.
Study NCT05468372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment.
Study NCT05866718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Compassionate Touch Intervention
Description: Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
Study NCT06483282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
Study NCT06644053 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quantified analysis of walking during a crossing task through different horizontal openings
Description: Functional test that reproduce a task of daily living
Study NCT06643403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen 100% Gas for Inhalation
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for max. 45 minutes
Study NCT04315883 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Assessment
Description: Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database
Study NCT04315883 — intervention group
Intervention type: RADIATION
Intervention: Transarterial Radioembolization
Description: Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate
Study NCT05919589 — intervention group
Intervention type: OTHER
Intervention: Care Integration for Children With Special Health Care Needs
Description: The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
Study NCT06474702 — intervention group
Intervention type: DEVICE
Intervention: 'Fitbit charge 4' 'smart-watch'-
Description: smartwatch device that collects physiological measures
Study NCT04792008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YQ23
Description: Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
Study NCT04792008 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Single dose of 0.9% normal saline via intravenous route as matching placebo
Study NCT06101030 — intervention group
Intervention type: DEVICE
Intervention: Signal On
Description: InSee monitor patient signals are on.
Study NCT05629364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIO-101
Description: Randomized, Controlled
Study NCT05629364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KIO-101
Description: Randomized, Controlled
Study NCT06250530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High tibial osteotomy using TOMOFIX
Description: TOMOFIX: A guidepin is placed to determine the level and length of the osteotomy with an appropriate hinge position selected. The oscillating saw is then used along with osteotomes to complete the osteotomy under image intensifier guidance. This is opened to the desired width of correction with a trapezoidal gap noted when using laminar spreader in the posterior position to avoid slope change. The plate is then applied and secured as per manufacturers operative technique.
Study NCT06250530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy using BodyCAD
Description: BodyCAD: The patient specific cutting block is applied to the proximal tibia and secured in placed. The osteotomy is then created with sequential drills and osteotome and opened to the predetermined correction as per the manufacturer's guidelines. The plate is applied and secured with the supplied screws.
Study NCT05866718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassionate Touch Intervention
Description: Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
Study NCT05866718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Formation Tools
Description: Participants will receive evidence-based tools for promoting habit-formation.
Study NCT04769115 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alert for temperature delta
Description: If alert for potential complications refer to appropriate specialist
Study NCT05750706 — intervention group
Intervention type: OTHER
Intervention: observation of invasive fungal infections
Description: observation of invasive fungal infections during chemotherapy
Study NCT05279690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
Study NCT05027802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: Palovarotene will be taken orally once daily at approximately the same time each day.
Study NCT06565117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: White yu green skin lotion
Description: Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
Study NCT05928988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8554；Itraconazole
Description: Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
Study NCT04870788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Relaxation
Description: Participate in mindfulness program
Study NCT04870788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04870788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04870788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group II (mindfulness waitlist)
Description: Patients and their partners participate in mindfulness program together or separately, depending on their preference, as in Group I beginning 12 weeks after starting the study and completing the third study visit.
Study NCT06293339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CHMI with 3D7 malaria
Description: Controlled human malaria infection with 3D7 malaria through mosquito bites
Study NCT06293339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHMI with 3D7 malaria
Description: Controlled human malaria infection with 3D7 malaria through mosquito bites
Study NCT04900298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeHaven Automated Hand Hygiene Device
Description: Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
Study NCT05523258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognition training
Description: The researchers distribute tablet computers for the patients. The patients in this group receive cognitive function training under the guidance of a full-time cognitive function trainer. The training time is about 45-60 minutes every time, and the frequency is twice a day until the operation. After the operation, cognitive function training should be started as soon as possible when the patient meets the following conditions including Glasgow score ≥ 12, no mechanical ventilation and no sedative drugs. The training intensity is the same as that before operation, generally starting from the 2nd to 3rd day after operation and continuing to discharge or the 7th day after operation.
Study NCT05523258 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Basic training based on tablet computer
Description: The researchers distribute the same tablet computer to the patients. The patients in this group receive basic training under the guidance of a full-time cognitive function trainer. The training duration is the same as that of the test group.
Study NCT04806113 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Moderna COVID-19 vaccine
Description: Two doses from the Moderna vaccine will be administered intramuscularly. The time between dose 1 and dose 2 of the vaccine will be 28 days.
Study NCT05427890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T2D Risk Communication Tool: Relative Risk
Description: Risk of T2D is presented in comparison to the rest of the Singapore population in a scale 1-10. Suggestions on different lifestyle changes and its potential to reduce the individual's relative risk is presented for user to observe impact of preventative behaviours.
Study NCT05427890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T2D Risk Communication Tool: Metabolic Age
Description: Risk of T2D is presented as an age, compared to their chronological age as a proxy for their current health status. Suggestions on different lifestyle changes and its potential to reduce the individual's metabolic age is presented for user to observe impact of preventative behaviours.
Study NCT05427890 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: T2D Risk Communication Tool: Traffic Light
Description: Risk of T2D is presented as either High (Red) or Low (Green). Generic tips on how to reduce risk of diabetes are included. This imitates the tool that is currently available for residents of Singapore to use to assess their risk of T2D.
Study NCT06051500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nostril focus followed by belly focus
Description: Focused breathing on the nostrils followed by focus breathing on the belly.
Study NCT06051500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belly focus followed by nostril focus
Description: Focused breathing on the bellyfollowed by focus breathing on the nostrils.
Study NCT04656561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX007
Description: Form: solution for injection; Route of Administration: IVT
Study NCT06171295 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood draw
Description: The blood draws in specified time points
Study NCT05257785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lymfit exercise intervention
Description: Participants randomized to this arm will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed. Participants will be followed-up at 6 months and 12 months.
Study NCT04656561 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Form and Route of Administration: pressure to mimic IVT injection
Study NCT05647616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
Study NCT06136416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire for Non-dystrophic myotonias
Description: Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
Study NCT05306392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moderate Hypothermia
Description: moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
Study NCT06417060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal block anesthesia
Description: Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
Study NCT06417060 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dorsal penile block anesthesia
Description: Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
Study NCT05306392 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Normothermia
Description: Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
Study NCT05257785 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist control
Description: Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
Study NCT05735886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Softgel containing placebo
Description: Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
Study NCT05735886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Softgel containing 250mg of Urolithin A (Mitopure)
Description: Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
Study NCT05647707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.